2019年1月8日 · Anti-interleukin-5 therapy is approved for patients with refractory asthma with an eosinophilic phenotype. The severe asthma care team at Mayo Clinic has expertise in identifying appropriate patients for this step-up therapy.

2015年10月8日 · The introduction of mepolizumab, a fully humanized monoclonal antibody that binds to IL-5, may represent a useful therapeutic option to control exacerbations and improve asthma-related quality of life in a subgroup of patients with persistent airway eosinophilia and moderate to severe asthma.

The TRFK5 monoclonal antibody reacts with mouse and human interleukin-5 (IL-5), a 26 kDa homodimeric cytokine. IL-5 stimulates B lymphocyte differentiation and proliferation and increases the secretion of IgM and IgA. It is also a key mediator in eosinophil activation and differentiation.

2021年7月23日 · Aims: GSK3511294 is a humanized anti-interleukin (IL)-5 monoclonal antibody (mAb) engineered for extended half-life and improved IL-5 affinity versus other anti-IL-5 mAbs. This study examined its safety, tolerability, pharmacokinetics (PK) and effect on …

Objective: We sought to develop a novel humanized anti-IL-5 receptor alpha (IL-5Ralpha) mAb with enhanced effector function (MEDI-563) that potently depletes circulating and tissue-resident eosinophils and basophils for the treatment of asthma. Methods: We used surface plasmon resonance to determine the binding affinity of MEDI-563 to FcgammaRIIIa.

Long-acting Anti-IL-5 mAb (GlaxoSmithKline Plc): 一种IL-5抑制剂药物，由GSK Plc (GSK Plc)公司最早进行研发，目前全球最高研发状态为临床1期，作用机制: IL-5抑制剂 (白细胞介素-5抑制剂)，治疗领域: 免疫系统疾病,呼吸系统疾病，在研适应症: 哮喘，在研机构: GSK Plc。

2023年4月4日 · We investigated the efficacy and safety of anti-interleukin (IL)-5/IL-5 receptor α chain (Rα) monoclonal antibodies (mAbs) in patients with ABPA complicated by asthma. ABPA cases treated with...

2016年4月4日 · Benralizumab, also known as MEDI-563, is a novel investigational mAb in the management of asthma and COPD. It has a unique mode of action. It binds to the α chain of the IL-5 receptor (IL-5Rα), a receptor expressed by mature eosinophils, eosinophil-lineage progenitor cells, and basophils.

long-acting anti-IL-5 mAb (GSK)是由葛兰素史克研发的一种人源化单克隆抗体，是一种IL5抑制剂。 目前该药物最高研发阶段为临床一期，用于治疗哮喘。 long-acting anti-IL-5 mAb (GSK)-靶点: IL5_适应症: 哮喘-临床_专利_批准

The ongoing anti-IL5 clinical trials, show promise of a safe, effective treatment option for the severe ‘eosinophilic’ asthma endotype independent of their atopic status . Beyond asthma, small pilot studies have documented their potential in treating HES and EGPA patients.